Structure-dependent inhibition of the human α1β2γ2 GABAA receptor by piperazine derivatives: A novel mode of action

NeuroToxicology

Volumn 51, Issue , 2015, Pages 1-9

  Hondebrink, Laura ^a   Hermans, Elise J P ^b   Schmeink, Stijn ^b   van Kleef, Regina G D M ^b   Meulenbelt, Jan ^a,b   Westerink, Remco H S ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

1(3 (Trifluoromethyl)phenyl)piperazine (TFMPP); 1 Benzylpiperazine (BZP); Antidepressants; Catecholamine; Drugs of abuse; Oocytes

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (2 CHLOROPHENYL)PIPERAZINE; 1 (2 METHOXYPHENYL)PIPERAZINE; 1 (2 METHYLBENZYL)PIPERAZINE; 1 (3 METHOXYPHENYL)PIPERAZINE; 1 (3 METHYLBENZYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 (4 CHLOROPHENYL)PIPERAZINE; 1 (4 FLUOROPHENYL)PIPERAZINE; 1 (4 METHOXYPHENYL)PIPERAZINE; 1 (4 METHYLBENZYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 2 (3 METHOXYPHENYL)PIPERAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 CHLOROPHENYLPIPERAZINE; CATECHOLAMINE; DIAZEPAM; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; PIPERAZINE;

AGONIST POTENCY; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EC50; FEMALE; GABAERGIC SYSTEM; HUMAN; INHIBITORY CONCENTRATION; INHIBITORY CONCENTRATION 20; ION CURRENT; NEUROTRANSMISSION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VOLTAGE CLAMP TECHNIQUE; XENOPUS LAEVIS; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; DIAZEPAM; GABA-A RECEPTOR ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; PIPERAZINES; PSYCHOTROPIC DRUGS; RECEPTORS, GABA-A; XENOPUS LAEVIS;

EID: 84941279403     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2015.09.002     Document Type: Article

References (28)

1. Arbo M.D., Bastos M.L., Carmo H.F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012, 122(3):174-185.
2. Brown D.D. A tribute to the Xenopus laevis oocyte and egg. J. Biol. Chem. 2004, 279(44):45291-45299.
3. D'Hulst C., Atack J.R., Kooy R.F. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov. Today 2009, 14(17-18):866-875.
4. DeVane C.L., Boulton D.W., Miller L.F., Miller R.L. Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int. J. Neuropsychopharmacol. 1999, 2:17-23.
5. EMCDDA, European Monitoring Centre for Drugs and Drug Addiction Annual Report 2012: The State of the Drugs Problem in Europe 2012, ISBN 978-92-9168-538-7. 10.2810/64775.
6. Fernandes E.C., Hendriks H.S., van Kleef R.G., Reniers A., Andersson P.L., van den B.M., Westerink R.H. Activation and potentiation of human GABAA receptors by non-dioxin-like PCBs depends on chlorination pattern. Toxicol. Sci. 2010, 118(1):183-190.
7. Hall B.J., Chebib M., Hanrahan J.R., Johnston G.A.R. Flumazenil-independent positive modulation of γ-aminobutyric acid action by 6-methylflavone at human α1β2γ2L and α1β2GABAA receptors. Eur. J. Pharmacol. 2004, 491:1-8.
8. Hendriks H.S., Antunes Fernandes E.C., Bergman A., van den Berg M., Westerink R.H. PCB-47, PBDE-47, and 6-OH-PBDE-47 differentially modulate human GABAA and alpha4beta2 nicotinic acetylcholine receptors. Toxicol. Sci. 2010, 118(2):635-642.
9. Hondebrink L., Meulenbelt J., van Kleef R.G., van den Berg M., Westerink R.H. Modulation of human GABAA receptor function: a novel mode of action of drugs of abuse. Neurotoxicology 2011, 32(6):823-827.
10. 2 GABAA receptors by mixtures of commonly used drugs of abuse. Neurotoxicology 2013, 35:23-29.
11. Kahn R.S., Wetzler S., Asnis G.M., Kling M.A., Suckow R.F., van Praag H.M. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology (Berl) 1990, 100(3):339-344.
12. Kiyatkin E.A., Rebec G.V. Heterogeneity of ventral tegmental area neurons: single-unit recording and iontophoresis in awake, unrestrained rats. Neuroscience 1998, 85(4):1285-1309.
13. Klaassen T., Ho Pian K.L., Westenberg H.G., den Boer J.A., van Praag H.M. Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res. 1998, 79(3):207-212.
14. Kovaleva J., Devuyst E., De P.P., Verstraete A. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther. Drug Monit. 2008, 30(3):394-398.
15. Martinez M.A., Ballesteros S., Sanchez de la T.C., Almarza E. Investigation of a fatality due to trazodone poisoning: case report and literature review. J. Anal. Toxicol. 2005, 29(4):262-268.
16. McKernan R.M., Whiting P.J. Which GABAA-receptor subtypes really occur in the brain?. Trends Neurosci. 1996, 19(4):139-143.
17. Miller R.L., DeVane C.L. Analysis of trazodone and m-chlorophenylpiperazine in plasma and brain tissue by high-performance liquid chromatography. J. Chromatogr. 1986, 374:388-393.
18. Nagai F., Nonaka R., Satoh Hisashi K.K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 2007, 559(2-3):132-137.
19. Ngo A.S., Anthony C.R., Samuel M., Wong E., Ponampalam R. Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department?. Resuscitation 2007, 74(1):27-37.
20. Rotzinger S., Fang J., Coutts R.T., Baker G.B. Human CYP2D6 and metabolism of m-chlorophenyl-piperazine. Biol. Psychiatry 1998, 44(11):1185-1191.
21. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10(9):685-697.
22. Schep L.J., Slaughter R.J., Vale J.A., Beasley D.M., Gee P. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin. Toxicol. (Phila.) 2011, 49(3):131-141.
23. Sevy S., Brown S.L., Wetzler S., Kotler M., Molcho A., Plutchik R., van Praag H.M. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res. 1994, 53(3):219-229.
24. Smith T.M., Suckow R.F. Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology 1985, 24(11):1067-1071.
25. Stein D.J., Hollander E., DeCaria C.M., Simeon D., Cohen L., Aronowitz B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Biol. Psychiatry 1996, 40(6):508-513.
26. Walters R.J., Hadley S.H., Morris K.D.W., Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat. Neurosci. 2000, 3(12):1274-1281.
27. WHO World Health Organization and Expert Committee on Drug Dependence. 1-(3-chlorophenyl)piperazine (mCPP) Pre-Review Report. Thirty-fifth Meeting 2012, ECDD.
28. Wood D.M., Dargan P.I., Button J., Holt D.W., Ovaska H., Ramsey J., Jones A.L. Collapse, reported seizure-and an unexpected pill. Lancet 2007, 369(9571):1490.